drugset / Trial / NCT03473613
Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
RandomizedParallel-groupOpen-labelPrevention
Summary
Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention
Timeline
- Start
- 2014-10-01
- Primary completion
- 2017-04-15
- Completion
- 2017-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cabergoline | Small molecule | 0.5 mg | Oral |
| Comparator | calcium gluconate | Small molecule | 10 ml | Intravenous |
| Comparator | calcium gluconate | Small molecule | 10 % | Intravenous |